Cite
HARVARD Citation
Chilvers, M. et al. (2021). Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Lancet. 9 (7), pp. 721-732. [Online].